Clin2
NCT07013916Possibly a fitRecruiting

Fructose and liver health in fatty liver disease

MASH - Metabolic Dysfunction-Associated SteatohepatitisMASH With FibrosisSteatosis of Liver

Part of Digestive system clinical trials.

This study looks at how a sugar called fructose affects inflammation and metabolism in people with a type of fatty liver disease called MASH. It aims to find out if fructose plays a role in making the disease worse.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
72 people
Ages
45 years to 65 years
Study type
Interventional

Who can take part

  • You are between 45 and 65 years old
  • You are overweight according to adjusted BMI guidelines for your ethnic group
  • You have been diagnosed with MASH (a serious form of fatty liver disease) with moderate liver scarring (F2-F3), or you have fatty liver without significant scarring, or you are a healthy volunteer without fatty liver
  • You do not have diabetes, and your average blood sugar (HbA1c) is below a certain level
  • You are not a heavy drinker, smoker, or taking certain medications like steroids, antibiotics, or weight loss drugs

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07581951Not yet recruiting· Phase 3
Study of HSK31679 for people with MASH (liver scarring)

This trial tests a new medicine, HSK31679, for people with MASH (a type of fatty liver disease with inflammation and scarring). It aims to see if the drug can help improve liver health.

NCT05651724Recruiting
MASH screening study for people with diabetes or obesity

This study screens participants for MASH (a type of liver fat inflammation) using information about your health and risk factors. It may help you and your care team learn whether you could have MASH and need follow-up.

Brussels, Vlaams-brabant
NCT06215716Recruiting· Phase 3
Efruxifermin for NASH/MASH with liver scarring

This study tests a new medicine, efruxifermin, for people with NASH/MASH (fatty liver disease) and moderate liver scarring. It aims to see if the drug can help improve the liver's condition.

Birmingham, Alabama
NCT06539494Recruiting· Phase 2
Fructose and Fatty Liver Study (MARTINI)

This study looks at how the body handles a sugar called fructose in people with and without fatty liver disease. It aims to understand how fructose contributes to liver fat buildup.

Amsterdam
NCT07209202Recruiting
Study on Fructose Handling in Obesity

This study looks at how the body handles fructose (a natural sugar) in people with different weights. It may help explain why some people process sugars differently.

Vallejo, California
NCT05528471Recruiting
Test whether fructose affects fatty liver in teens

This study looks at how fructose (a type of sugar) may affect fatty liver disease (NAFLD) in teens with obesity. The goal is to learn whether fructose changes liver health, using MRI/MRS scans to measure the liver.

Edmonton, Alberta

Hear when a new MASH - Metabolic Dysfunction-Associated Steatohepatitis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.